#Global Trends – Page 4 – HEALTHCARE INSIGHTS

Key Development On August 26, 2026, clinical-stage biopharmaceutical innovator Biohaven Ltd. (NYSE: BHVN) announced a definitive worldwide licensing agreement transferring... Read more

Tag: #Global Trends

Precision Oncology & Companion Diagnostics: US FDA Approves Roche’s PATHWAY HER2 (4B5) and VENTANA HER2 Dual ISH Assays as First Companion Diagnostics for HER2-Positive Esophageal and Metastatic Gastroesophageal Adenocarcinoma (GEA) to Direct ZIIHERA® Therapy

Biopharmaceutical Services & Oncology M&A: McKesson Expands Clinical Research and Commercialization Platform with $2.25 Billion Acquisition of Precision Medicine Group

Personalized Immuno-Oncology & mRNA Therapeutics: How the Merck/Moderna Neoantigen Vaccine (Intismeran Autogene) Functions, Pivotal Clinical Milestones, and Scalability Roadblocks in ‘N-of-1’ Biomanufacturing

Cell Therapy Manufacturing Bottlenecks: Bristol Myers Squibb Terminates $380 Million Commercial CAR-T Manufacturing Agreement with Cellares, Triggering 100 Workforce Layoffs

MedTech & Biosensing Innovation: US FDA Authorizes Abbott’s Libre Duo® 10 Day as World’s First Continuous Glucose and Ketone Monitoring (CGKM) Wearable for Diabetes Management

MedTech Cybersecurity & Supply Chain Disruption: Boston Scientific Discloses Cyber Incident Impacting Global Order Processing and Shipments – Wall Street Models Up to 700 bps Q3 Revenue Exposure

Asia-Pacific Cardiometabolic Expansion: China NMPA Accepts Novo Nordisk’s Marketing Authorization Application for Oral Wegovy® (Semaglutide) to Contest Eli Lilly in $4.5 Billion Market

Neuroscience Licensing & Capital De-Risking: Biohaven Monetizes Lead Focal Epilepsy Candidate Opakalim (Kv7 Platform) to SK Biopharmaceuticals in $795 Million Strategic Divestment

Health Economics & Real-World Outcomes: Sustained Zepbound® (Tirzepatide) Use Associated with Up to 38% Reduction in Monthly Healthcare Costs Among Older Adults with Obesity After 12 Months

Facebook

Map

Online Members